Gesamtlänge aller Episoden: 5 days 18 hours 23 minutes
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations
Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not